Literature DB >> 29976914

Ag₂O on ZrO₂ as a Recyclable Catalyst for Multicomponent Synthesis of Indenopyrimidine Derivatives.

Sandeep V H S Bhaskaruni1, Suresh Maddila2, Werner E van Zyl3, Sreekantha B Jonnalagadda4.   

Abstract

We describe the synthesis of silver loaded on zirconia and its use as an efficient catalyst for a one-pot three-component reaction to synthesize 11 indenopyrimidine derivatives, of which 7 are new compounds. The procedure involves substituted benzaldehydes, indane-1,3-dione, and guanidinium hydrochloride, with ethanol as solvent. The proposed green protocol at room temperature is simple and efficient, giving excellent yields (90⁻96%) in short reaction times (<30 min). The protocol works well according to the green chemistry principles with respect to high atom economy, no need for column separation, and reusability of the catalyst, which are attractive features. XRD, TEM, SEM, and BET analysis were used to characterize the catalyst materials.

Entities:  

Keywords:  Ag2O/ZrO2; green chemistry; heterogeneous catalysis; indenopyrimidines; mixed oxides; no column chromatography

Mesh:

Substances:

Year:  2018        PMID: 29976914      PMCID: PMC6100188          DOI: 10.3390/molecules23071648

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Multicomponent reactions (MCRs) are cherished protocols in organic synthesis due to their vast potential in the fields of medicinal, pharmaceutical, and agro-chemistry [1]. MCRs are different from the other classical synthesis approaches due to their facile synthesis protocols, high atom efficiency, high yields, and minimal by-product formation [2]. Further, the efficacy of MCRs when compared with multistep synthetic protocols lies in the selective formation of several bonds in a single reaction flask with highly desirable yield over a short interval of time [3]. Currently, heterogeneous catalysts play a key role in organic synthesis because they meet most of the goals of green and sustainable chemistry [4]. Researchers have made remarkable improvements in the design of well-defined catalyst materials. Innovative methods have allowed the coherent design and preparation of very active and selective catalyst materials by governing the structure and composition of the active particles [5]. Furthermore, heterogeneous catalysts offer many benefits in synthetic transformations such as outstanding chemical and thermal stability, noncorrosiveness, nonflammability, eco-friendliness, nontoxicity, ease of separation, reusability, and commercial availability [6]. In recent years, zirconium oxide (ZrO2) have been effusively revealed as a catalyst or a supported catalyst in various potential chemical applications due to its extensive properties such as acidic and basic sites [7], high stability in the presence of redox conditions, active phase support, and chemical consistency related to other supports like alumina and silica. Further, ZrO2 is low cost, stable, nonhazardous, reusable, and readily available [8]. Silver salts are widely used as catalysts and their efficacy has been demonstrated in terms of being cost-effective, non-toxic, simple to handle, and appropriate for usage as a one-electron redox system [9]. However, their use in large amounts is unwarranted, but if used in a green-manner as a recyclable catalyst, it has many advantages. Hence, the use of silver-loaded zirconia catalysts is a desirable choice for eco-friendly synthesis. Among the known heterocyclic compounds, N-heterocyclic scaffolds are very important in medicinal chemistry [10]. In the N-heterocyclic class of scaffolds, pyrimidine and its derivatives play a prominent role [11]. Being the main constituents of several natural products, these pyrimidines represent a significant class of molecules which have been of increased interest in recent years owing to their valuable pharmacological and biological applications in antimicrobial [12], antifungal [13], anti-tumor [14], anti-HIV [15], anti-tubercular [16], anti-inflammatory [17], and antimalarial [18] activities. Moreover, aryl-indenopyrimidines have been used as adenosine A2A receptor antagonists [19], which are useful, and many reports have dealt with the preparation of different types of pyrimidine derivatives via multicomponent reactions. Owing to their economic viability and scientific importance, methodologies have been described for the synthesis of various types of substituted pyrimidines. Diverse catalytic systems such as NaOH, references [20,21,22] sodium methoxide [23], 1-sulfonic acid-3-methyl imidazolium ferric chloride/NaY [24], α-Fe2O3-MCM-41-P [25], and uranyl acetate/succinimide sulfonic acid [26] have been used in the synthesis of pyrimidine derivatives. However, these protocols invariably demand expensive reagents, high energy input, and lengthy reaction times. Other limitations are lower yields and the need for solvents and column separations. There is, thus, a demand for a greener preparation method for indenopyrimidines. We found no literature reports to date using metal complexes or metal oxides as catalysts in their synthesis. Although silver-loaded ZrO2 have been reported as a catalyst for varied reactions [27,28], no protocols have been described for the synthesis of indenopyrimidines via MCRs. We recently reported several green synthetic approaches of various medicinally interesting heterocyclic scaffolds [29,30,31,32,33,34,35,36,37]. Encouraged by those favorable results with different substituted heterocyclic scaffolds, here we describe the synthesis and characterization of silver loaded on zirconia and its efficiency in the one-pot synthesis of functionalized indenopyrimidines via a three-component reaction at room temperature (RT).

2. Experimental Section

2.1. Catalyst Preparation

Supported catalysts with different wt % (weight percentage) of silver-loaded zirconia (1, 2.5, and 5.0 wt %) were synthesized following a wet impregnation process [38,39]. The solid heterogeneous catalyst was prepared by combining zirconia (ZrO2, 3 g, Alfa Aesar, Ward Hill, MA, USA) and a suitable quantity of silver chloride (AgCl2, Alfa Aesar) dissolved in distillated water (60 mL). The mixture was stirred at room temperature (RT) for 5–7 h. After this time, the ensuing slurry was filtered under vacuum. It was dried in an oven at 120–130 °C for 6 h and calcined in the presence of air at 450 °C for 5 h to afford the (1.0, 2.5, and 5.0 wt %) silver on zirconia.

2.2. General Procedure for the Synthesis of Indenopyrimidine Derivatives

In a typical reaction, an equimolar mixture of aldehydes (1 mmol), indane-1,3-dione (1 mmol), and guanidinium hydrochloride (1 mmol) were dissolved in ethanol (5 mL) at RT, followed by the addition of Ag2OZrO2 (60 mg) as a catalyst. The reaction mixture was held at RT for 30 min under stirring (Scheme 1), while the reaction progress was monitored by TLC at regular time intervals. When the reaction was complete, the mixture was filtered, and ethyl acetate was used to extract the filtrate which was then evaporated under reduced pressure to obtain the crude product and washed with ethanol. The reaction product was recrystallized in ethanol to obtain the pure target compound. The yields reported are the weighed values after recrystallization and isolation. The products were further characterized by 1H-NMR, 13C-NMR, HRMS, and FT-IR analysis. The related details and spectra are given in the Supplementary Information File (SI-II & III).
Scheme 1

Synthesis of novel indenopyrimidine derivatives. RT = room temperature.

2-Amino-4-(2-methoxyphenyl)-5H-indeno[1,2–d]-pyrimidine-5-one (4a). 1H-NMR (DMSO-d6, 400 MHz) δ = 3.83 (s, 3H, -OCH3), 7.09 (d, J = 7.6 Hz, 1H, Ar-H), 7.16 (d, J = 8.16 Hz, 1H, Ar-H), 7.61 (t, J = 1.2 Hz, 1H, Ar-H), 7.92–7.95 (m, 4H, Ar-H), 8.22 (s, 2H, -NH2), 8.77–8.79 (m, 1H, Ar-H). 13C-NMR δ = 56.03, 111.56, 120.10, 121.00, 122.94, 122.98, 128.16, 133.09, 135.69, 135.78, 135.86, 138.96, 139.32, 141.79, 160.05, 188.50, 189.61; FT-IR: 3269.10 (-NH), 2957.02 (-CH), 1710 (-C=O), 1593.28 (-C=C), 1483.73 (-C=N), 733.81 (-CH). 2-Amino-4-(4-methoxyphenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4b). 1H-NMR (DMSO-d6, 400 MHz) δ = 3.89 (s, 3H, -OCH3), 7.13 (d, J = 8.92 Hz, 2H, Ar-H), 7.80 (s, 2H, -NH2), 7.71 (s, 2H, NH2), 7.93–7.95 (m, 4H, Ar-H), 8.60 (d, J = 8.92 Hz, 2H, Ar-H). 13C-NMR δ = 55.72, 114.49, 122.86, 125.86, 126.28, 135.54, 135.69, 136.98, 139.27, 141.69, 145.72, 163.77, 188.96, 189.80; FT-IR: 3010.13 (-NH), 2941.01 (-CH), 1712.14 (-C=O), 1673.42 (-C=C), 1468.81 (-C=N), 771.95 (-CH); HRMS of [C18H13N3O2 + H]+ (m/z): 304.0766; Calcd: 304.0763. 2-Amino-4-(2,3-dimethoxyphenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4c). 1H-NMR (DMSO-d6, 400 MHz) δ = 3.91 (s, 6H, -OCH3), 7.21 (t, J = 8.08 Hz, 1H, Ar-H), 7.32–7.34 (m, 1H, Ar-H), 7.94–8.14 (m, 4H, Ar-H), 8.36 (s, 2H, -NH2), 8.38 (t, J = 1.04 Hz, 1H, Ar-H). 13C-NMR δ = 55.95, 61.49, 118.22, 123.05, 123.10, 123.61, 124.23, 126.21, 129.53, 136.02, 139.00, 139.42, 141.89, 150.23, 152.19; FT-IR: 3087.99 (-NH), 2939.24 (-CH), 1711.98 (-C=O), 1673.55 (-C=C), 1469.79 (-C=N), 771.94 (-CH); HRMS of [C19H15N3O3 + H]+ (m/z): 334.0992; Calcd: 334.1008. 2-Amino-4-(2,5-dimethoxyphenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4d). 1H-NMR (DMSO-d6, 400 MHz) δ = 3.82 (s, 3H, -OCH3), 3.89 (s, 3H, -OCH3), 7.11 (d, J = 9.12 Hz, 1H, Ar-H), 7.21 (d, J = 3.12 Hz, 1H, Ar-H), 7.93–7.97 (m, 4H, Ar-H), 8.23 (s, 2H, -NH2), 8.64 (d, J = 3.2 Hz, 1H, ArH). 13C-NMR δ = 55.51, 56.38, 112.72, 116.49, 121.32, 123.07, 128.11, 135.75, 135.89, 138.84, 139.29, 141.87, 152.29, 154.92, 188.82, 189.64, 206.58; FT-IR: 3087.87 (-NH), 2950.12 (-CH), 1746.67 (-C=O), 1683.90 (-C=C), 1588.60 (-C=N), 780.18 (-CH); HRMS of [C19H15N3O3 + H]+ (m/z): 334.0434; Calcd: 334.0441. 2-Amino-4-(2-bromophenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4e). 1H-NMR (DMSO-d6, 400 MHz) δ = 7.52–7.59 (m, 2H, NH2), 7.89–7.98 (m, 7H, Ar-H), 8.00 (s, 1H, Ar-H). 13C-NMR δ = 122.83, 122.91, 124.36, 130.67, 132.12, 132.32, 135.70, 135.92, 140.42, 141.20, 141.35, 141.67, 142.03, 142.98, 197.19, 198.68; FT-IR: 3089.08 (-NH), 2941.43 (-CH), 1745.65 (-C=O), 1673.02 (-C=C), 1564.46 (-C=N), 771.47 (-CH), 619.03 (-C-Br); HRMS of [C17H10BrN3O + H]+ (m/z): 353.1042; Calcd: 353.1042. 2-Amino-4-(2-fluorophenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4f). 1H-NMR (DMSO-d6, 400 MHz) δ =7.39 (s, 1H, NH2), 7.68 (t, J = 1.08 Hz, 2H, Ar-H), 7.92–7.99 (m, 6H, Ar-H). 13C-NMR δ = 115.65, 115.86, 123.24, 124.49, 124.52, 133.07, 136.07, 136.21, 139.60, 141.99, 160.66, 188.07, 188.85, 197.56, 198.69; FT-IR: 3275.94 (-NH), 2956.87 (-CH), 1740.56 (-C=O), 1620.19 (-C=C), 1485.01 (-C=N), 1008.10 (-C-F), 757.33 (-CH); HRMS of [C17H10BrN3O + H]+ (m/z): 292.0732; Calcd: 292.0732. 2-Amino-4-(3,4-dimethoxyphenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4g). 1H-NMR (DMSO-d6, 400 MHz) δ = 3.90 (d, J = 3.84 Hz, 6H, -OCH3), 7.16 (d, J = 8.52 Hz, 1H, Ar-H), 7.80 (s, 1H, NH2), 7.92–7.97 (m, 4H, Ar-H), 8.02–8.04 (m, 1H, Ar-H), 8.68 (d, J = 1.92 Hz, 1H, ArH). 13C-NMR δ = 55.18, 111.53, 115.74, 122.78, 122.91, 126.09, 131.08, 135.56, 135.69, 139.22, 146.43, 148.31, 153.91, 189.85; FT-IR: 3088.10 (-NH), 2942.06 (-CH), 1712.66 (-C=O), 1673.31 (-C=C), 1468.88 (-C=N), 772.61 (-CH), 801.96 (-CH). 2-Amino-4-(3-hydroxyphenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4h). 1H-NMR (DMSO-d6, 400 MHz) δ = 7.01–7.04 (m, 1H, Ar-H), 7.35 (t, J = 7.88 Hz, 1H, Ar-H), 7.71 (s, 2H, NH2), 7.82 (d, J = 7.72 Hz, 1H, Ar-H), 7.92–7.96 (m, 5H, Ar-H), 9.86 (s, 1H, -OH). 13C-NMR δ = 119.61, 120.67, 123.00, 123.04, 125.46, 128.94, 129.69, 133.84, 135.77, 135.93, 139.33, 141.89, 145.82, 157.33, 188.45, 189.43; FT-IR: 3241.25 (-OH), 3088.13 (-NH), 1745.77 (-C=O), 1665.42 (-C=C), 1484.83 (-C=N), 780.62 (-CH); HRMS of [C17H11N3O2 + H]+ (m/z): 290.0732; Calcd: 290.0732. 2-Amino-4-(4-bromophenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4i). 1H-NMR (DMSO-d6, 400 MHz) δ = 7.77 (d, J = 8.52 Hz, 2H, Ar-H), 7.81 (s, J = 8.56 Hz, 2H, -NH2), 7.95–7.99 (m, 4H, Ar-H), 8.41 (d, J = 8.52 Hz, 2H, Ar-H). 13C-NMR δ = 103.27, 109.58, 110.67, 112.60, 116.48, 136.51, 143.42, 151.63, 151.95, 152.67, 167.34, 194.19; FT-IR: 3087.96 (-NH), 1724.92 (-C=O), 1685.17 (-C=C), 1485.31 (-C=N), 828.42 (-CH), 606.46 (-C-Br). 2-Amino-4-(4-chlorophenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4j). 1H-NMR (DMSO-d6, 400 MHz) δ = 7.36 (d, J = 8.52 Hz, 2H, -NH2), 7.64 (d, J = 8.56 Hz, 1H, Ar-H), 7.85–7.97 (m, 6H, Ar-H), 7.82 (d, J = 7.72 Hz, 1H, Ar-H), 8.51 (d, J = 8.6 Hz, 1H, Ar-H). 13C-NMR δ = 122.57, 122.79, 123.13, 127.74, 127.82, 128.85, 130.79, 135.36, 135.59, 137.85, 141.51, 143.73, 197.94, 198.14, 199.07; FT-IR: 3089.02 (-NH), 1712.07 (-C=O), 1673.33 (-C=C), 1469.06 (-C=N), 802.02 (-CH), 702.10 (-C-Cl); HRMS of [C17H10ClN3O + H]+ (m/z): 308.1139; Calcd: 308.114. 2-Amino-4-(4-ethylphenyl)-5H-indeno[1,2-d]-pyrimidine-5-one (4k). 1H-NMR (DMSO-d6, 400 MHz) δ = 1.22 (t, J = 7.56 Hz, 3H, -CH3), 2.68–2.79 (m, 2H, -CH2), 7.42 (d, J = 8.2 Hz, 2H, Ar-H), 7.83 (s, 2H, -NH2), 7.93–7.96 (m, 4H, Ar-H), 8.46 (d, J = 8.24 Hz, 2H, Ar-H). 13C-NMR δ = 15.03, 28.42, 30.63, 122.56, 122.98, 123.04, 128.30, 130.48, 134.22, 135.57, 135.75, 135.90, 139.39, 141.86, 142.99, 145.64, 150.32, 188.69, 189.56, 206.47; FT-IR: 3088.40 (-NH), 2941.60 (-CH), 1712.33 (-C=O), 1673.31 (-C=C), 1469.87 (-C=N), 802.02 (-CH).

3. Results and Discussion

3.1. Crystallinity by Powder XRD (PXRD) Studies

Figure 1 illustrates the crystalline phases of calcined silver oxidezirconia catalyst material. The PXRD patterns of the catalytic sample display the major 2θ peak values at 24.2°, 28.2°, 31.3°, 35.4°, 40.5°, 45.0°, 50.3°, 55.4°, and 60.1° corresponding to zirconia; the peak values were correlated with the international standard file (JCPDS file no. 37-1484). In addition, the catalyst material revealed diffraction patterns at 2θ angles of 38.1°, 44.3°, 64.4°, and 77.4° corresponding to the Ag2O (JCPDS file no 72-2108). The peaks recognized in the diffractogram indicate the polycrystalline nature of the catalyst materials. Further, the average crystallite size of the catalyst was measured by the Debye–Scherrer formula using the strongest maximum-intensity diffraction peak, about 9.2 nm for 2.5% Ag2O/ZrO2.
Figure 1

Powder X-ray diffractogram of 2.5% Ag2O–ZrO2 catalyst.

3.2. TEM Analysis

The transition electron microscopy images (Figure 2) provide the morphology of prepared Ag2O/ZrO2 of different wt %. In this image, the silver oxide particle dimensions are mostly in the range between 10 and 16 nm, with black spherical shapes and seemingly well distributed. Further, zirconia is revealed as white globular-shaped particles. It is clearly observed that 1% has a lesser dispersion of Ag, whereas 5% has more Ag agglomerated on the surface of Zr, which fails to provide more active sites to facilitate the reaction. Changes in the morphology of the recovered catalyst after reaction were marginal.
Figure 2

TEM micrographs of 1%, 2.5%, and 5% Ag2O–ZrO2 catalyst.

3.3. SEM Analysis

The morphology and size dispersion of the catalyst material were determined with SEM analysis. In Figure 3, a large number of white and irregular shapes are observed for 2.5% Ag2O loaded on ZrO2. Small silver oxide particles were revealed as white irregular aggregates on the zirconia surface. The micrographs from SEM–EDX validate the even distribution of silver oxide on the zirconia surface. Results also confirm the data from ICP elemental analysis. The mapping also shows the presence of Ag on ZrO2. Furthermore, the morphology of the catalyst from the SEM images also shows the crystallinity and homogeneity of the sample.
Figure 3

(A) SEM micrograph; (B) SEM mapping; (C) EDS spectra of 2.5% Ag2O–ZrO2 catalyst.

3.4. BET Surface Area Analysis

The nitrogen adsorption/desorption isotherm and resulting pore size dispersion of the 2.5% Ag2O/ZrO2 catalyst material is shown in Figure 4. The catalyst material exhibits a type IV isotherm with the presence of a typical H2 hysteresis loop, which designates the mesoporous nature of the material as per the IUPAC classification. The Barrett-Joyner-Halenda (BJH) pore size distribution describes a mesoporous texture for the material, and the isotherm P/Po range was 0.61–0.98. The BET surface area was measured at 89.52 m2/g with a pore volume of 0.330 cm³/g and pore size of 10.3 nm. The ICP study indicates the presence of >1.98 wt % of silver in the catalyst material.
Figure 4

N2 adsorption–desorption isotherms of 2.5% Ag2O–ZrO2 catalyst.

3.5. Pyridine Adsorbed FT-IR Spectroscopy

The nature of acidic sites on the 2.5% Ag2O-loaded ZrO2 surface was examined by employing ex situ pyridine FT-IR spectroscopy (Figure 5) [40]. Infrared (IR) spectra were recorded on a Perkin Elmer Precisely equipped with a Universal ATR sampling accessory using a diamond crystal. The powdered material was placed on the crystal and a force of 120 psi was applied to ensure proper contact between the material and the crystal. The spectra were analyzed using Spectrum 100 software. Before recording the IR spectra, pyridine was adsorbed by placing a drop of pyridine on 10 mg of the sample followed by evacuation in air for 1 h at room temperature to remove reversibly adsorbed pyridine on the surface of the catalyst. The IR band at 1540 cm−1 confirmed the presence of Brønsted acidic sites (B). The peak observed at 1485 cm−1 is attributed to both Brønsted and Lewis acidic sites (B + L). The prominent absorption band at 1450 cm−1 is due to the pyridine adsorbed on Lewis acidic sites (L) of the catalyst. The presence of more Lewis acidic sites on the catalyst surface than Brønsted acidic sites is shown in Figure 5. Generally, more Lewis acidic sites are anticipated in the Ag2OZrO2 catalyst due to the availability of vacant metal orbitals on the surface of the catalyst, which are capable of accepting electron pairs from the electron-rich species [41]. Except for the assigned peaks, the other IR bands are mostly less intensive, mainly due to the signal-to-noise ratio, which was unavoidable.
Figure 5

Pyridine FT-IR spectra of 2.5% Ag2O/ZrO2 catalyst. B = Brønsted acidic sites; L = Lewis acidic sites; B + L = Brønsted and Lewis acidic sites.

4. Reaction Optimization

For optimization of the reaction conditions for a one-pot, three-component reaction involving 2-methoxy benzaldehyde (1 mmol), indane-1,3-dione (1 mmol), and guanidinium hydrochloride (1 mmol), various reaction conditions such as effect of temperature, solvents, and catalysts were investigated. In the absence of solvent and catalyst, no product occurred at RT or under reflux conditions, even after 10 h of reaction (Table 1, entries 1 and 2). The reaction was carried out in ethanol in the presence of various basic catalysts like TEA, pyridine, NaOH, and K2CO3 at RT; only trace amounts of material were obtained (Table 1, entries 3–6). Reactions with ionic liquids such as (Bmim) BF4 or L-proline (Table 1, entries 7 and 8) as a catalyst gave low yields. When the reaction was conducted using acidic catalysts such as AcOH, FeCl3, and PTSA, moderate yields of product were attained after 4 h (Table 1, entries 9–11). Consequently, reaction was attempted in presence of pure metal oxide catalysts, such as SiO2, ZrO2, and Al2O3, and the reaction showed good yields after 2.0–3.0 h reaction time (Table 1, entries 12–14). Based on the promising outcome with zirconia oxide, to enhance the reaction performance, the efficiencies of different metal oxides loaded on zirconia, such as 2.5% CuO/ZrO2, MnO2/ZrO2, and Ag2O/ZrO2, were examined. These mixed-oxide heterogeneous catalysts gave very good to excellent yields (82–96%) (Table 1, entries 15–17), while the best result was obtained with Ag2O/ZrO2 (96% yield, 30 min). Bimetallic metal oxides showed higher activity than their parent metal oxides, presumably due to a better distribution of the active metal on the support and the synergistic activity between the loaded and support materials, providing optimum distribution and increased number of active sites compared to their oxide homologues.
Table 1

Effect of catalysts on the synthesis of 4a a.

EntryCatalystSolventConditionTime (h)Yield (%) b
1----RT10--
2----Reflux10--
3TEAEtOHRT8.09
4PyridineEtOHRT8.513
5NaOHEtOHRT7.525
6K2CO3EtOHRT7.019
7(Bmim)BF4EtOHRT1023
8L-prolineEtOHRT1027
9AcOHEtOHRT5.043
10FeCl3EtOHRT4.550
11PTSAEtOHRT5.045
12SiO2EtOHRT2.562
13ZrO2EtOHRT2.079
14Al2O3EtOHRT3.059
152.5% CuO/ZrO2EtOHRT1.582
162.5% MnO2/ZrO2EtOHRT1.087
172.5% Ag2O/ZrO2EtOHRT0.2096

a All products were characterized by 1H-NMR, 13C-NMR, HRMS, and FT-IR spectral analysis. b Isolated yields after recrystallization. -- No reaction.

The effect of solvents on the title reaction was investigated in the presence of varied nonpolar solvents. No reaction occurred in n-hexane or toluene. When the reaction was performed in polar aprotic solvents such as THF, DMF, and MeCN, the yield of product was low. In the polar protic solvent MeOH, the yield was good, but lower than that with EtOH. Hence, EtOH was chosen as the solvent for the remainder of the studies. The optimized results are shown in Table 2 (entries 1–8).
Table 2

Optimization of various solvent conditions for the model reaction a.

EntrySolventTime (min)Yield (%)
1No solvent120--
2n-hexane120--
3toluene90--
4THF7510
5DMF6518
6MeCN6025
7MeOH4581
8EtOH3096

a Reaction conditions: arylaldehyde (1), (1 mmol), 1,3-Indandione (1 mmol) (2), and guanidinium hydrochloride (3) (1 mmol) and solvent (5 mL) were stirred at room temperature. -- No isolated yields.

Assuming silver oxide loaded on zirconia as the ideal model catalyst, the contribution of % silver loading on zirconia was investigated at 1.0%, 2.5%, and 5.0% Ag2O/ZrO2. While 1% Ag loading gave a 90% yield in 45 min, relative to the 2.5% Ag, the 5% Ag neither improved the yield nor decreased the reaction time. The best activity was observed with 2.5% Ag2O/ZrO2; hence, this was taken as the optimum loading. This could be due to the optimum dispersion of Ag2O on ZrO2, when compared to 5% Ag2O//ZrO2, where dispersion was less uniform due to the possible aggregation of silver particles. Hence, catalytic activity was lower compared to the 2.5% loading. The 2.5% loading recorded greater activity than 1% Ag2O//ZrO2. Possibly, the former had more active sites than the latter (Figure 2). A discussion on the role of the Lewis acidic sites in the reaction is part of the mechanism section (Scheme 2). The efficacy of the reaction, including yield and reaction times for 2.5 wt % Ag2O/ZrO2, is summarized in Table 3. An increase in catalyst amount from 20 mg to 60 mg improved the yield from 52% to 96% and reduced the reaction time. The increase in the product may be attributed to the comparative increase in the number of available active sites, possibly accelerating the reaction. An increase in the amount of catalyst from 60 mg to 120 mg registered no significant change in the yield of product or reaction time. Hence, 60 mg of the catalyst was considered the ideal amount for the chosen synthesis.
Scheme 2

Probable mechanism for the synthesis of novel indenopyrimidine derivatives.

Table 3

Optimization of various weight % for the model reaction with 2.5% Ag2O/ZrO2 catalyst a.

EntryCatalyst (mg)Time (min)Yield (%)
12010056
2405079
3603096
4803096
51003096
61204096

a Reaction conditions: arylaldehyde (1) (1 mmol), 1,3-indanedione (2) (1 mmol), and guanidine hydrochloride (3) (1 mmol) and catalyst and solvent (5 mL) were stirred at room temperature.

Encouraged by the results, we further explored the applicability of the protocol for other substituted aldehydes under the optimized reaction conditions, by using 10 other substituted aldehydes. The corresponding indenopyrimidines afforded excellent yields in similar reaction times (30 min) (Table 4, entries 1–11). All the reactions, irrespective of electron-withdrawing or electron-donating groups at ortho, meta, or para positions, generally gave excellent yields. All the product molecules were fully characterized by employing 1H-NMR, 13C-NMR, FT-IR, and HRMS spectral analysis.
Table 4

Synthesis of novel functionalized pyridine derivatives by 2.5% Ag2O/ZrO2 catalyst a.

EntryRProductYield * (%)m.p. (°C)Lit. m.p. (°C)
12-OMe 4a 94119–121-
24-OMe 4b 93136–137100 [20]
32,3-(OMe)2 4c 94183–184-
42,5-(OMe)2 4d 92200–201-
52-Br 4e 94197–198-
62-F 4f 92239–241-
73,4-(OMe)2 4g 96176–178178 [20]
83-OH 4h 95246–248-
94-Br 4i 94221–223210 [20]
104-Cl 4j 90239–241244 [20]
114-Et 4k 94204–206-

a Reaction conditions: arylaldehyde (1) (1 mmol), 1,3-indanedione (2) (1 mmol), and guanidine hydrochloride (3) (1 mmol), catalyst (60 mg), and ethanol solvent (5 mL) were stirred at room temperature. R = substituted benzaldehydes. - New compounds/no literature (lit.) data. * = Isolated yields after recrystallization.

A proposed mechanism for the one-pot three-component reaction is outlined in Scheme 2. The presence of Lewis acidic sites on the catalyst surface facilitates the reactants to undergo reaction in a shorter time. It is assumed that in the first step, the Lewis acidic sites with the carbonyl oxygen generate the carbonium ion (a) [42]. In a fast reaction with the carbonium ion, the active methylene group affords intermediate (b), which desorbs from the catalyst surface by abstracting a proton from the protic solvent, EtOH (b), to form (c). On further dehydration (c), it produces the condensation product (A). Next, a Michael addition occurs between the intermediate (A) and the guanidinium, followed by cyclization and aromatization, and the transient intermediate yields the target compound—the substituted pyrimidine-5-one derivative. The catalytic efficiency of the Ag2O/ZrO2 on the title reaction in comparison with other reported catalysts is summarized in the Table 5.
Table 5

A comparison table with various other catalysts for synthesizing pyrimidine derivatives.

CatalystSolventReaction ConditionYield (%) [Ref]
NaOHEtOHReflux, 6–10 h81–94 [20]
NaOHEtOHReflux, 7–8.4 h75–86 [21]
NaOHEtOHReflux, 0.5–1 h85–94 [22]
NaOMeEtOHReflux, 10–14 h60–70 [23]
α-Fe2O3-MCM-41-PSolvent free80 °C, 1 h82–95 [25]
Uranyl acetate/succinimide sulfonic acidSolvent free90 °C, 4 h75–96 [26]
2.5% Ag2O–ZrO2EtOHRT, 30 min90–96 [Present Work]

5. Reusability of Catalyst

The main objective and attraction of heterogeneous catalysts are its reusability. We thus examined the recovery and reusability of the Ag2O/ZrO2 catalyst. The solid catalyst from the reaction mixture was separated by simple filtration under vacuum, followed by washing with acetone solvent and drying at 100 °C for 3 h. The recovered catalyst was reused in subsequent reactions. Six runs in successive reactions gave yields without significant loss in product yield (Figure 6).
Figure 6

Recyclability of the Ag2O/ZrO2 catalyst.

6. Conclusions

In conclusion, we report a simple and green protocol for the synthesis of indenopyrimidines by a three-component reaction. All the reactions involving the reaction of 11 different aromatic aldehydes with 1,3-indandione and guanidinium hydrochloride using (2.5%) silver loaded on a zirconia catalyst gave excellent yields (90–96%). The proposed catalyst proved efficient, stable, and reusable. This method offers easy workup, excellent selectivity, and high yields in short reaction times at room temperature using ethanol, a green solvent. All the products were purified by recrystallization from ethanol. This method needs no chromatographic separation. Consequently, the use of volatile and hazardous solvents has been evaded. This method is useful for synthesizing various privileged pyrimidine scaffolds in short times in a one-pot strategy under green conditions.
  9 in total

Review 1.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

2.  Synthesis, anti-inflammatory, ulcerogenic and cyclooxygenase activities of indenopyrimidine derivatives.

Authors:  Santosh S Undare; Navanath J Valekar; Ajinkya A Patravale; Dattatraya K Jamale; Sunil S Vibhute; Laxman S Walekar; Govind B Kolekar; M B Deshmukh; Prashant V Anbhule
Journal:  Bioorg Med Chem Lett       Date:  2015-12-28       Impact factor: 2.823

Review 3.  Small heterocycles in multicomponent reactions.

Authors:  Benjamin H Rotstein; Serge Zaretsky; Vishal Rai; Andrei K Yudin
Journal:  Chem Rev       Date:  2014-07-17       Impact factor: 60.622

4.  Synthesis and in vitro anticancer and antitubercular activity of diarylpyrazole ligated dihydropyrimidines possessing lipophilic carbamoyl group.

Authors:  Rama Krishna Yadlapalli; O P Chourasia; Kiranmayi Vemuri; Manjula Sritharan; Ramu Sridhar Perali
Journal:  Bioorg Med Chem Lett       Date:  2012-03-07       Impact factor: 2.823

5.  Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A)/A(1) antagonist by minimizing bioactivation to an iminium ion reactive intermediate.

Authors:  Heng-Keang Lim; Jie Chen; Carlo Sensenhauser; Kevin Cook; Robert Preston; Tynisha Thomas; Brian Shook; Paul F Jackson; Stefanie Rassnick; Kenneth Rhodes; Vedwatee Gopaul; Rhys Salter; Jose Silva; David C Evans
Journal:  Chem Res Toxicol       Date:  2011-06-28       Impact factor: 3.739

6.  Synthesis, biological properties and anti-HIV-1 activity of new pyrimidine P1,P2-dinucleotides.

Authors:  A Miazga; P Ziemkowski; M A Siwecka; A Lipniacki; A Piasek; T Kulikowski
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2010-06       Impact factor: 1.381

7.  Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6- dideoxy-L-ascorbic acid.

Authors:  S Raić-Malić; D Svedruzić; T Gazivoda; A Marunović; A Hergold-Brundić; A Nagl; J Balzarini; E De Clercq; M Mintas
Journal:  J Med Chem       Date:  2000-12-14       Impact factor: 7.446

8.  Synthesis and anti-inflammatory activity of new alkyl-substituted phthalimide 1H-1,2,3-triazole derivatives.

Authors:  Shalom Pôrto de Oliveira Assis; Moara Targino da Silva; Ronaldo Nascimento de Oliveira; Vera Lúcia de Menezes Lima
Journal:  ScientificWorldJournal       Date:  2012-12-05

9.  Nanostructured Samarium Doped Fluorapatites and Their Catalytic Activity towards Synthesis of 1,2,4-Triazoles.

Authors:  Kranthi Kumar Gangu; Suresh Maddila; Surya Narayana Maddila; Sreekantha B Jonnalagadda
Journal:  Molecules       Date:  2016-09-24       Impact factor: 4.411

  9 in total
  1 in total

1.  Four-Component Fusion Protocol with NiO/ZrO2 as a Robust Recyclable Catalyst for Novel 1,4-Dihydropyridines.

Authors:  Sandeep V H S Bhaskaruni; Suresh Maddila; Werner E van Zyl; Sreekantha B Jonnalagadda
Journal:  ACS Omega       Date:  2019-12-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.